StockData
TuHURA Biosciences, Inc./NV logo

TuHURA Biosciences, Inc./NV (HURA) company profile

HURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 0/30
$1.36−0.01 (-0.73%)

Close on Nov 19, 2026Market cap $86.67MP/E –Yield –

About TuHURA Biosciences

Pharmaceutical Preparations, SIC 2834

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology biopharmaceutical company focused on developing therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company’s pipeline utilizes three core technologies: the proprietary Immune Fx (IFx) platform, VISTA-inhibiting monoclonal antibodies, and Delta Opioid Receptor (DOR) targeting antibody-drug conjugates. Its lead candidate, IFx-2.0, is designed to stimulate innate immune responses against tumors and is in clinical testing as an adjunctive treatment for advanced Merkel cell carcinoma. Additional assets include TBS-2025 for acute myeloid leukemia and bi-functional antibody-drug conjugates targeting immunosuppressive myeloid-derived suppressor cells. Target end users are cancer patients with refractory disease or unmet therapeutic needs.

The company operates as a clinical-stage development enterprise without commercial sales channels or retail store networks. Its operations and clinical research initiatives are based in the United States, and it is incorporated under the laws of Nevada. TuHURA Biosciences does not state the location of its corporate headquarters in the provided text.

Summary of the business section of TuHURA Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
TuHURA Biosciences, Inc./NV
Founded
2009
Headquarters
Tampa, FL
Address
10500 University Center Dr., Suite 110 33612
Phone
(813) 875-6600
Employees
22, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
Cherry Bekaert LLP, Tampa, Florida

Stock & identifiers

Ticker
HURA
Former tickers
KTRA until Oct 21, 2024; DMPI until Sep 18, 2020
Exchange
Nasdaq
IPO date
Feb 22, 2013
Shares outstanding
64M, Aug 11, 2026
Public float
$111.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-35 reverse, Oct 18, 2024; 1-for-50 reverse, Nov 14, 2022; 1-for-10 reverse, May 8, 2019; 1-for-4 reverse, Sep 13, 2016
SEC CIK
1498382
CUSIP
898920103
ISIN
US8989201038
FIGI
BBG001J7N7K8
Share class FIGI
BBG001V0HK36
LEI
549300N7OBMRNSOQC133
EIN
99-0360497

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
James A. BiancoChief Executive Officer, Director2,098,307
Dan DearbornChief Financial Officer0
Robert E. HoffmanDirector68,902
George K. NgDirector0
Alan ListDirector0
James S. J. ManusoDirector0
Craig TendlerDirector0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.99M$1.78M$1.83M$0–
FY2024
Dr Bianco
$6.07M$5.32M$1.72M$0–
FY2024
Robert Hoffman
$2.44M$2.44M$1.72M$0–
FY2023
Dr Bianco
$1.21M$1.21M$325.03K$4–
FY2023
Robert EHoffmann
$1.18M$559.02K$325.03K$4–
FY2023
Robert Hoffman
$1.18M$559.02K$325.03K$4–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Dr. James Bianco
President and Chief Executive Officer
$544.56K$490.54K$2.87M$80.00K$3.99M-34%
Dan Dearborn
Chief Financial Officer
$380.64K$163.39K$1.29M–$1.83M-37%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 22 full-time employees and no part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 30, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 30, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 7, 2025MergerRegistration of securities for a merger or exchange offer (S-4)
Jan 3, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 14, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 22, 2024Name changeName changed from Kintara Therapeutics, Inc. to TuHURA Biosciences, Inc./NV
Oct 21, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 30, 2024Late filingNotification of late filing
Jun 13, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 13, 2024MergerRegistration of securities for a merger or exchange offer (S-4)
Dec 15, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 5, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 26, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 3, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 6, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 21, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 21, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 18, 2020Name changeName changed from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc.
Jun 16, 2020MergerRegistration of securities for a merger or exchange offer (S-4)
Oct 1, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 27, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 1, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
May 29, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 31, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 3, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 3, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 7, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 8, 2016ListingRegistration of securities on an exchange (Form 8-A)
Mar 28, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 14, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)

See a number that looks wrong?